- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06577441
Testen van de toevoeging van een IDH2-remmer, enasidenib, aan de gebruikelijke behandeling (Cedazuridine-Decitabine) voor myelodysplastisch syndroom (MDS) met een hoger risico met IDH2-mutatie (een MyeloMATCH-behandelingsproef)
Een gerandomiseerd fase II-onderzoek naar op enasidenib gebaseerde therapieën versus cedazuridine-decitabine bij IDH2-gemuteerd myelodysplastisch syndroom met een hoger risico: een MyeloMATCH-behandelingsonderzoek
This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Enasidenib is an enzyme inhibitor that may stop the growth of cells by blocking some of the enzymes needed for cell growth. Giving ASTX727 in combination with enasidenib may be effective in treating patients with higher-risk IDH2-mutated MDS.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To compare the complete remission (CR) rate of enasidenib + decitabine and cedazuridine (ASTX727) and ASTX727 monotherapy in patients with higher-risk IDH2-mutated MDS using International Working Group 2023 (IWG2023) response criteria.
SECONDARY OBJECTIVES:
I. To estimate the median event-free survival (EFS) at designated time point(s) for each treatment arm.
II. To estimate the median overall survival (OS) at designated time point(s) for each treatment arm.
III. To estimate the frequency and severity of toxicities with each regimen in this patient population.
IV. To estimate the median time to response for each treatment arm. V. To estimate the median duration of response for each treatment arm. VI. To estimate the IDH2 variant allele frequency (VAF) reduction for each treatment arm.
VII. To estimate the rate of allogeneic hematopoietic cell transplantation for each treatment arm.
VIII. To compare rates of partial response (PR), CR with limited count recovery (CRL), CR with partial count recovery (CRh), and hematologic improvement (HI) using IWG 2023 response criteria between treatment arms.
IX. To compare the measurable residual disease (MRD) kinetics by flow cytometry and next generation sequencing (NGS) at designated time point(s) at the end of cycle 4 & 6 and to assess any correlation with clinical outcomes (e.g. CR, EFS, OS).
X. To estimate the median time to transformation of MDS to acute myeloid leukemia (AML).
EXPLORATORY OBJECTIVES:
I. To estimate CR rate, median EFS, and median OS in patients treated with ASTX727 monotherapy that crossover to the treatment arm with ASTX727 + enasidenib after 6 cycles if CR is not achieved.
II. To estimate CR rate, median EFS, and median OS for patients based on Molecular International Prognostic Scoring System (IPSS-M) prognostic risk score at diagnosis, stratified for score level.
III. To estimate concordance between centrally-performed molecular studies and cytogenetics to those done locally.
OUTLINE: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive ASTX727 orally (PO) once daily (QD) on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to Tier Advancement Pathway (TAP). Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
REGIMEN 2: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression.
After completion of study treatment, patients are followed up every 6 months for up to 5 years after registration.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
San Juan, Puerto Rico, 00927
- Werving
- Centro Comprensivo de Cancer de UPR
-
Hoofdonderzoeker:
- Luis J. Santos Reyes
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
San Juan, Puerto Rico, 00936
- Werving
- San Juan City Hospital
-
Hoofdonderzoeker:
- Luis J. Santos Reyes
-
Contact:
- Site Public Contact
- Telefoonnummer: 787-763-1296
-
-
-
-
California
-
Berkeley, California, Verenigde Staten, 94704
- Actief, niet wervend
- Alta Bates Summit Medical Center-Herrick Campus
-
Irvine, California, Verenigde Staten, 92612
- Werving
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Hoofdonderzoeker:
- Deepa Jeyakumar
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
Orange, California, Verenigde Staten, 92868
- Werving
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Deepa Jeyakumar
-
Contact:
- Site Public Contact
- Telefoonnummer: 877-827-8839
- E-mail: ucstudy@uci.edu
-
San Mateo, California, Verenigde Staten, 94401
- Actief, niet wervend
- Mills Health Center
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Werving
- UF Health Cancer Institute - Gainesville
-
Contact:
- Site Public Contact
- Telefoonnummer: 352-273-8010
-
Hoofdonderzoeker:
- Dina G. Khalaf
-
Miami, Florida, Verenigde Staten, 33176
- Werving
- Miami Cancer Institute
-
Hoofdonderzoeker:
- Firas El Chaer
-
Contact:
- Site Public Contact
- Telefoonnummer: 786-596-2000
-
Pembroke Pines, Florida, Verenigde Staten, 33028
- Werving
- Memorial Hospital West
-
Contact:
- Site Public Contact
- Telefoonnummer: 954-265-4325
-
Hoofdonderzoeker:
- Fernando M. Vargas Madueno
-
-
Georgia
-
Albany, Georgia, Verenigde Staten, 31701
- Werving
- Phoebe Putney Memorial Hospital
-
Hoofdonderzoeker:
- Vamsi Kota
-
Contact:
- Site Public Contact
- Telefoonnummer: 229-312-0405
- E-mail: ga_cares@augusta.edu
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Werving
- Saint Luke's Cancer Institute - Boise
-
Contact:
- Site Public Contact
- Telefoonnummer: 208-381-2774
- E-mail: eslinget@slhs.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Coeur d'Alene, Idaho, Verenigde Staten, 83814
- Werving
- Kootenai Health - Coeur d'Alene
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Fruitland, Idaho, Verenigde Staten, 83619
- Werving
- Saint Luke's Cancer Institute - Fruitland
-
Contact:
- Site Public Contact
- Telefoonnummer: 208-381-2774
- E-mail: eslinget@slhs.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Meridian, Idaho, Verenigde Staten, 83642
- Werving
- Saint Luke's Cancer Institute - Meridian
-
Contact:
- Site Public Contact
- Telefoonnummer: 208-381-2774
- E-mail: eslinget@slhs.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Nampa, Idaho, Verenigde Staten, 83687
- Werving
- Saint Luke's Cancer Institute - Nampa
-
Contact:
- Site Public Contact
- Telefoonnummer: 208-381-2774
- E-mail: eslinget@slhs.org
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Nampa, Idaho, Verenigde Staten, 83687
- Werving
- Saint Alphonsus Cancer Care Center-Nampa
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Post Falls, Idaho, Verenigde Staten, 83854
- Werving
- Kootenai Clinic Cancer Services - Post Falls
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Verenigde Staten, 83864
- Werving
- Kootenai Clinic Cancer Services - Sandpoint
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Bloomington, Illinois, Verenigde Staten, 61704
- Werving
- Illinois CancerCare-Bloomington
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Canton, Illinois, Verenigde Staten, 61520
- Werving
- Illinois CancerCare-Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Carthage, Illinois, Verenigde Staten, 62321
- Werving
- Illinois CancerCare-Carthage
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Anand A. Patel
-
Chicago, Illinois, Verenigde Staten, 60611
- Werving
- Northwestern University
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Chicago, Illinois, Verenigde Staten, 60625
- Werving
- Swedish Covenant Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-878-8200
-
Hoofdonderzoeker:
- Robert M. Eisner
-
Danville, Illinois, Verenigde Staten, 61832
- Werving
- Carle at The Riverfront
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@Carle.com
-
DeKalb, Illinois, Verenigde Staten, 60115
- Werving
- Northwestern Medicine Cancer Center Kishwaukee
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Cancer Care Specialists of Illinois - Decatur
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Verenigde Staten, 62526
- Werving
- Decatur Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Dixon, Illinois, Verenigde Staten, 61021
- Werving
- Illinois CancerCare-Dixon
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 815-285-7800
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Carle Physician Group-Effingham
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Effingham, Illinois, Verenigde Staten, 62401
- Werving
- Crossroads Cancer Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Eureka, Illinois, Verenigde Staten, 61530
- Werving
- Illinois CancerCare-Eureka
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Evanston, Illinois, Verenigde Staten, 60201
- Werving
- NorthShore University HealthSystem-Evanston Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-570-2109
-
Hoofdonderzoeker:
- Robert M. Eisner
-
Galesburg, Illinois, Verenigde Staten, 61401
- Werving
- Illinois CancerCare-Galesburg
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Geneva, Illinois, Verenigde Staten, 60134
- Werving
- Northwestern Medicine Cancer Center Delnor
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Glenview, Illinois, Verenigde Staten, 60026
- Werving
- NorthShore University HealthSystem-Glenbrook Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-570-2109
-
Hoofdonderzoeker:
- Robert M. Eisner
-
Glenview, Illinois, Verenigde Staten, 60026
- Werving
- Northwestern Medicine Glenview Outpatient Center
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Grayslake, Illinois, Verenigde Staten, 60030
- Werving
- Northwestern Medicine Grayslake Outpatient Center
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Contact:
- Site Public Contact
- Telefoonnummer: 312-695-1102
-
Highland Park, Illinois, Verenigde Staten, 60035
- Werving
- NorthShore University HealthSystem-Highland Park Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 847-570-2109
-
Hoofdonderzoeker:
- Robert M. Eisner
-
Hines, Illinois, Verenigde Staten, 60141
- Werving
- Edward Hines Jr VA Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 708-202-8387
-
Hoofdonderzoeker:
- Jorgena Kosti-Schwartz
-
Kewanee, Illinois, Verenigde Staten, 61443
- Werving
- Illinois CancerCare-Kewanee Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Lake Forest, Illinois, Verenigde Staten, 60045
- Werving
- Northwestern Medicine Lake Forest Hospital
-
Contact:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Macomb, Illinois, Verenigde Staten, 61455
- Werving
- Illinois CancerCare-Macomb
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Mattoon, Illinois, Verenigde Staten, 61938
- Werving
- Carle Physician Group-Mattoon/Charleston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Maywood, Illinois, Verenigde Staten, 60153
- Werving
- Loyola University Medical Center
-
Hoofdonderzoeker:
- Stephanie B. Tsai
-
Contact:
- Site Public Contact
- Telefoonnummer: 708-226-4357
-
New Lenox, Illinois, Verenigde Staten, 60451
- Werving
- UC Comprehensive Cancer Center at Silver Cross
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Anand A. Patel
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- Cancer Care Center of O'Fallon
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
O'Fallon, Illinois, Verenigde Staten, 62269
- Werving
- HSHS Saint Elizabeth's Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Orland Park, Illinois, Verenigde Staten, 60462
- Werving
- University of Chicago Medicine-Orland Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Anand A. Patel
-
Orland Park, Illinois, Verenigde Staten, 60462
- Werving
- Northwestern Medicine Orland Park
-
Contact:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Ottawa, Illinois, Verenigde Staten, 61350
- Werving
- Illinois CancerCare-Ottawa Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Pekin, Illinois, Verenigde Staten, 61554
- Werving
- Illinois CancerCare-Pekin
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Peoria, Illinois, Verenigde Staten, 61615
- Werving
- Illinois CancerCare-Peoria
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Peru, Illinois, Verenigde Staten, 61354
- Werving
- Illinois CancerCare-Peru
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Princeton, Illinois, Verenigde Staten, 61356
- Werving
- Illinois CancerCare-Princeton
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Southern Illinois University School of Medicine
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-545-7929
-
Springfield, Illinois, Verenigde Staten, 62702
- Werving
- Springfield Clinic
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-444-7541
-
Springfield, Illinois, Verenigde Staten, 62781
- Werving
- Springfield Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Verenigde Staten, 61801
- Werving
- Carle Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-446-5532
- E-mail: Research@carle.com
-
Hoofdonderzoeker:
- Vamsi K. Vasireddy
-
Warrenville, Illinois, Verenigde Staten, 60555
- Werving
- Northwestern Medicine Cancer Center Warrenville
-
Contact:
- Site Public Contact
- Telefoonnummer: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Hoofdonderzoeker:
- Yasmin Abaza
-
Washington, Illinois, Verenigde Staten, 61571
- Werving
- Illinois CancerCare - Washington
-
Contact:
- Site Public Contact
- Telefoonnummer: 309-243-3605
- E-mail: andersonj@illinoiscancercare.com
-
Hoofdonderzoeker:
- Bryan A. Faller
-
-
Indiana
-
Crown Point, Indiana, Verenigde Staten, 46307
- Werving
- UChicago Medicine Northwest Indiana
-
Contact:
- Site Public Contact
- Telefoonnummer: 855-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hoofdonderzoeker:
- Anand A. Patel
-
-
Iowa
-
Ankeny, Iowa, Verenigde Staten, 50023
- Werving
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Clive, Iowa, Verenigde Staten, 50325
- Werving
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- Mercy Medical Center - Des Moines
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Richard L. Deming
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- Iowa Methodist Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-6727
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50309
- Werving
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Verenigde Staten, 50314
- Werving
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa/Holden Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-237-1225
-
Hoofdonderzoeker:
- Prajwal Dhakal
-
Pella, Iowa, Verenigde Staten, 50219
- Werving
- UI Healthcare Mission Cancer and Blood - Pella
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-282-2921
- E-mail: trials@missioncancer.com
-
Waukee, Iowa, Verenigde Staten, 50263
- Werving
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 515-241-3305
-
Hoofdonderzoeker:
- Seema Harichand-Herdt
-
-
Kansas
-
Fairway, Kansas, Verenigde Staten, 66205
- Werving
- University of Kansas Clinical Research Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Hoofdonderzoeker:
- Jesus Gonzalez Lugo
-
Kansas City, Kansas, Verenigde Staten, 66160
- Werving
- University of Kansas Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Hoofdonderzoeker:
- Jesus Gonzalez Lugo
-
Westwood, Kansas, Verenigde Staten, 66205
- Werving
- University of Kansas Hospital-Westwood Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 913-588-3671
- E-mail: KUCC_Navigation@kumc.edu
-
Hoofdonderzoeker:
- Jesus Gonzalez Lugo
-
-
Kentucky
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- The James Graham Brown Cancer Center at University of Louisville
-
Hoofdonderzoeker:
- Mohamed M. Hegazi
-
Contact:
- Site Public Contact
- Telefoonnummer: 502-562-3429
-
Louisville, Kentucky, Verenigde Staten, 40245
- Werving
- UofL Health Medical Center Northeast
-
Hoofdonderzoeker:
- Mohamed M. Hegazi
-
Contact:
- Site Public Contact
- Telefoonnummer: 502-852-2755
- E-mail: ctoinfo@louisville.edu
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70805
- Werving
- LSU Health Baton Rouge-North Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-765-7659
- E-mail: research@ololrmc.com
-
Hoofdonderzoeker:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Werving
- Our Lady of The Lake
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-765-7659
-
Hoofdonderzoeker:
- Harry G. Sequeira Gross
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Werving
- Our Lady of the Lake Physician Group
-
Contact:
- Site Public Contact
- Telefoonnummer: 225-765-7659
- E-mail: research@ololrmc.com
-
Hoofdonderzoeker:
- Harry G. Sequeira Gross
-
-
Maryland
-
Bethesda, Maryland, Verenigde Staten, 20889-5600
- Werving
- Walter Reed National Military Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 301-319-2100
-
Hoofdonderzoeker:
- Ryan Jones
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Werving
- Tufts Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 617-636-5000
- E-mail: ContactUsCancerCenter@TuftsMedicalCenter.org
-
Hoofdonderzoeker:
- Andreas K. Klein
-
-
Michigan
-
Brighton, Michigan, Verenigde Staten, 48114
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Canton, Michigan, Verenigde Staten, 48188
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Chelsea, Michigan, Verenigde Staten, 48118
- Werving
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Genesys Hurley Cancer Institute
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Flint, Michigan, Verenigde Staten, 48503
- Geschorst
- Genesee Hematology Oncology PC
-
Flint, Michigan, Verenigde Staten, 48503
- Werving
- Cancer Hematology Centers - Flint
-
Contact:
- Site Public Contact
- Telefoonnummer: 810-762-8038
- E-mail: wstrong@ghci.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Livonia, Michigan, Verenigde Staten, 48154
- Werving
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Pontiac, Michigan, Verenigde Staten, 48341
- Werving
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
Ypsilanti, Michigan, Verenigde Staten, 48197
- Werving
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contact:
- Site Public Contact
- Telefoonnummer: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Hoofdonderzoeker:
- Elie G. Dib
-
-
Minnesota
-
Brainerd, Minnesota, Verenigde Staten, 56401
- Werving
- Essentia Health Saint Joseph's Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Deer River, Minnesota, Verenigde Staten, 56636
- Werving
- Essentia Health - Deer River Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Duluth, Minnesota, Verenigde Staten, 55805
- Werving
- Essentia Health Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Fairview Southdale Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Edina, Minnesota, Verenigde Staten, 55435
- Werving
- Minnesota Oncology - Edina
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Hibbing, Minnesota, Verenigde Staten, 55746
- Werving
- Essentia Health Hibbing Clinic
-
Hoofdonderzoeker:
- Bret E. Friday
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Werving
- Abbott-Northwestern Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Werving
- Hennepin County Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Werving
- Park Nicollet Clinic - Saint Louis Park
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Saint Paul, Minnesota, Verenigde Staten, 55101
- Werving
- Regions Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- Werving
- United Hospital
-
Contact:
- Site Public Contact
- Telefoonnummer: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Hoofdonderzoeker:
- Yan Ji
-
Sandstone, Minnesota, Verenigde Staten, 55072
- Werving
- Essentia Health Sandstone
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Virginia, Minnesota, Verenigde Staten, 55792
- Werving
- Essentia Health Virginia Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
-
Missouri
-
Farmington, Missouri, Verenigde Staten, 63640
- Werving
- Parkland Health Center - Farmington
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Sainte Genevieve, Missouri, Verenigde Staten, 63670
- Werving
- Sainte Genevieve County Memorial Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
St Louis, Missouri, Verenigde Staten, 63131
- Werving
- Missouri Baptist Medical Center
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
Sullivan, Missouri, Verenigde Staten, 63080
- Werving
- Missouri Baptist Sullivan Hospital
-
Hoofdonderzoeker:
- Bryan A. Faller
-
Contact:
- Site Public Contact
- Telefoonnummer: 314-996-5569
-
-
Montana
-
Anaconda, Montana, Verenigde Staten, 59711
- Werving
- Community Hospital of Anaconda
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Verenigde Staten, 59101
- Werving
- Billings Clinic Cancer Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-996-2663
- E-mail: research@billingsclinic.org
-
Bozeman, Montana, Verenigde Staten, 59715
- Werving
- Bozeman Health Deaconess Hospital
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Great Falls, Montana, Verenigde Staten, 59405
- Werving
- Benefis Sletten Cancer Institute
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Verenigde Staten, 59901
- Werving
- Logan Health Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Verenigde Staten, 59804
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- John M. Schallenkamp
-
Contact:
- Site Public Contact
- Telefoonnummer: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Verenigde Staten, 03756
- Werving
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Hoofdonderzoeker:
- Patrick W. Mellors
-
-
New Jersey
-
Livingston, New Jersey, Verenigde Staten, 07039
- Werving
- Cooperman Barnabas Medical Center
-
Hoofdonderzoeker:
- Neil D. Palmisiano
-
Contact:
- Site Public Contact
- Telefoonnummer: 973-322-5200
-
Long Branch, New Jersey, Verenigde Staten, 07740
- Werving
- Monmouth Medical Center
-
Hoofdonderzoeker:
- Neil D. Palmisiano
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-923-6564
- E-mail: mary.danish@rwjbh.org
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Werving
- Rutgers Cancer Institute of New Jersey
-
Hoofdonderzoeker:
- Neil D. Palmisiano
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-235-7356
-
Toms River, New Jersey, Verenigde Staten, 08755
- Werving
- Community Medical Center
-
Hoofdonderzoeker:
- Neil D. Palmisiano
-
Contact:
- Site Public Contact
- Telefoonnummer: 732-557-8294
- E-mail: Lennette.Gonzales@rwjbh.org
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- Werving
- University of New Mexico Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 505-925-0348
- E-mail: HSC-ClinicalTrialInfo@salud.unm.edu
-
Hoofdonderzoeker:
- Charles Foucar
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14263
- Werving
- Roswell Park Cancer Institute
-
Hoofdonderzoeker:
- Eunice S. Wang
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-767-9355
- E-mail: askroswell@roswellpark.org
-
Stony Brook, New York, Verenigde Staten, 11794
- Werving
- Stony Brook University Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-862-2215
-
Hoofdonderzoeker:
- Suhu Liu
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke University Medical Center
-
Hoofdonderzoeker:
- Harry P. Erba
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-275-3853
-
Greenville, North Carolina, Verenigde Staten, 27834
- Werving
- East Carolina University
-
Hoofdonderzoeker:
- Darla K. Liles
-
Contact:
- Site Public Contact
- Telefoonnummer: 252-744-1015
- E-mail: eubankss@ecu.edu
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58103
- Werving
- Essentia Health Cancer Center-South University Clinic
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Werving
- Ohio State University Comprehensive Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Hoofdonderzoeker:
- Jayanshu Jain
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- Werving
- University of Oklahoma Health Sciences Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Hoofdonderzoeker:
- Zimu Gong
-
-
Pennsylvania
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Werving
- Geisinger Medical Center
-
Hoofdonderzoeker:
- Joseph J. Vadakara
-
Contact:
- Site Public Contact
- Telefoonnummer: 570-271-5251
- E-mail: cancerresearch@geisinger.edu
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- Werving
- UPMC Hillman Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 412-647-8073
-
Hoofdonderzoeker:
- Annie P. Im
-
Wilkes-Barre, Pennsylvania, Verenigde Staten, 18711
- Werving
- Geisinger Wyoming Valley/Henry Cancer Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 570-271-5251
- E-mail: HemonCCTrials@geisinger.edu
-
Hoofdonderzoeker:
- Joseph J. Vadakara
-
-
South Carolina
-
Boiling Springs, South Carolina, Verenigde Staten, 29316
- Werving
- Prisma Health Cancer Institute - Spartanburg
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Easley, South Carolina, Verenigde Staten, 29640
- Werving
- Prisma Health Cancer Institute - Easley
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Verenigde Staten, 29605
- Werving
- Prisma Health Cancer Institute - Faris
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Verenigde Staten, 29605
- Werving
- Prisma Health Cancer Institute - Butternut
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Verenigde Staten, 29615
- Werving
- Prisma Health Cancer Institute - Eastside
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Greer, South Carolina, Verenigde Staten, 29650
- Werving
- Prisma Health Cancer Institute - Greer
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
Seneca, South Carolina, Verenigde Staten, 29672
- Werving
- Prisma Health Cancer Institute - Seneca
-
Hoofdonderzoeker:
- Suzanne R. Fanning
-
Contact:
- Site Public Contact
- Telefoonnummer: 864-522-4317
- E-mail: Kim.Williams3@prismahealth.org
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37920
- Geschorst
- University of Tennessee - Knoxville
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Werving
- Huntsman Cancer Institute/University of Utah
-
Contact:
- Site Public Contact
- Telefoonnummer: 888-424-2100
- E-mail: cancerinfo@hci.utah.edu
-
Hoofdonderzoeker:
- Paul J. Shami
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23298
- Werving
- VCU Massey Comprehensive Cancer Center
-
Hoofdonderzoeker:
- Keri R. Maher
-
Contact:
- Site Public Contact
- Telefoonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
-
Washington
-
Edmonds, Washington, Verenigde Staten, 98026
- Werving
- Swedish Cancer Institute-Edmonds
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Contact:
- Site Public Contact
- Telefoonnummer: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
Issaquah, Washington, Verenigde Staten, 98029
- Werving
- Swedish Cancer Institute-Issaquah
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Contact:
- Site Public Contact
- Telefoonnummer: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
Seattle, Washington, Verenigde Staten, 98122
- Werving
- Swedish Medical Center-First Hill
-
Hoofdonderzoeker:
- Charles W. Drescher
-
Contact:
- Site Public Contact
- Telefoonnummer: 206-215-2343
- E-mail: PCRC-NCORP@Swedish.org
-
-
Wisconsin
-
Ashland, Wisconsin, Verenigde Staten, 54806
- Werving
- Duluth Clinic Ashland
-
Contact:
- Site Public Contact
- Telefoonnummer: 218-786-3308
- E-mail: CancerTrials@EssentiaHealth.org
-
Hoofdonderzoeker:
- Bret E. Friday
-
Green Bay, Wisconsin, Verenigde Staten, 54301
- Werving
- Saint Vincent Hospital Cancer Center Green Bay
-
Hoofdonderzoeker:
- Anthony J. Jaslowski
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-433-8889
- E-mail: WI_research_admin@hshs.org
-
Green Bay, Wisconsin, Verenigde Staten, 54303
- Werving
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Hoofdonderzoeker:
- Anthony J. Jaslowski
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
La Crosse, Wisconsin, Verenigde Staten, 54601
- Werving
- Gundersen Lutheran Medical Center
-
Contact:
- Site Public Contact
- Telefoonnummer: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Hoofdonderzoeker:
- Michael O. Ojelabi
-
Madison, Wisconsin, Verenigde Staten, 53705
- Werving
- William S Middleton VA Medical Center
-
Hoofdonderzoeker:
- Christopher D. Fletcher
-
Contact:
- Site Public Contact
- Telefoonnummer: 17007 608-256-1901
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Werving
- Medical College of Wisconsin
-
Contact:
- Site Public Contact
- Telefoonnummer: 414-805-3666
-
Hoofdonderzoeker:
- Guru Subramanian Guru Murthy
-
Stevens Point, Wisconsin, Verenigde Staten, 54482
- Werving
- Marshfield Medical Center-River Region at Stevens Point
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Adedayo A. Onitilo
-
Sturgeon Bay, Wisconsin, Verenigde Staten, 54235-1495
- Werving
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Hoofdonderzoeker:
- Anthony J. Jaslowski
-
Contact:
- Site Public Contact
- Telefoonnummer: 920-433-8889
- E-mail: wi_research_admin@hshs.org
-
Weston, Wisconsin, Verenigde Staten, 54476
- Werving
- Marshfield Medical Center - Weston
-
Contact:
- Site Public Contact
- Telefoonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Hoofdonderzoeker:
- Adedayo A. Onitilo
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
GENERAL MYLEOMATCH REGISTRATION CRITERIA:
-
Patients must be registered to the Master Screening and Reassessment Protocol (MYELOMATCH) and assigned to this protocol by the MATCHBox Treatment Verification Team.
-
Participants must not have received prior anti-cancer therapy for AML or MDS.
- Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility.
-
Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which is allowed for urgent cytoreduction. The use of prior hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide is allowed
-
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients must have a morphologically-confirmed diagnosis of MDS with a Revised International Prognostic Scoring System (IPSS-R) score ≥ 4.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients must have a detectable pathogenic IDH2 mutation based on the National Cancer Institute (NCI) Myeloid Panel.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): No prior treatment with deoxyribonucleic acid (DNA) methyltransferase inhibitors (ASTX727, azacitidine, or decitabine).
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Prior treatment with growth factors (ESA, granulocyte colony-stimulating factor [g-CSF], thrombopoietin [TPO] agonist) or luspatercept is allowed.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Prior treatment with lenalidomide with a maximum limit of 1 month of exposure is allowed.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients with therapy-related MDS are allowed.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age ≥ 18 years.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Unless elevated due to Gilbert's syndrome. In patients with Gilbert's syndrome, if the total bilirubin is ≤ 3.0 x ULN, then they are eligible for enrollment.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase [SGPT]) ≤ 3.0 x upper limit of normal (ULN).
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Creatinine clearance ≥ 30 mL/min
- To be calculated using Cockroft Gault formula.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not pregnant and not nursing, because this study involves: an agent that has known genotoxic, mutagenic and teratogenic effects.
- Therefore, for women of childbearing potential only, a negative pregnancy test done as part of screening lab work prior to registration is required.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
-
REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Patients on the ASTX727 monotherapy arm (Regimen 1) that do not achieve a CR (complete response), CRL (CR with limited count recovery), or CRh (CR with partial count recovery) after completing 6 cycles of study treatment.
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): ECOG performance status ≤ 2.
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
- Unless elevated due to Gilbert's syndrome. In patients with Gilbert's syndrome if the total bilirubin is ≤ 3.0 x ULN, then they are eligible for enrollment.
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): AST (SGOT)/ALT (SGPT) ≤ 3.0 x upper limit of normal (ULN)
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Creatinine clearance ≥ 30 mL/min
- To be calculated using Cockroft Gault formula.
-
RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Not pregnant and not nursing, because this study involves: an agent that has known genotoxic, mutagenic and teratogenic effects.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Regimen 1 (ASTX727)
Patients receive ASTX727 PO QD on days 1-5 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Regimen 2. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Andere namen:
Undergo bone marrow aspiration Given PO
Andere namen:
Undergo buccal swab and blood sample collection
Andere namen:
|
|
Experimenteel: Regimen 2 (ASTX727, enasidenib)
Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study. Patients may also undergo optional buccal swab on study, and/or optional additional bone marrow aspiration and blood sample collection on study and at disease progression. |
Undergo bone marrow biopsy
Andere namen:
Undergo bone marrow aspiration Given PO
Andere namen:
Given PO
Andere namen:
Undergo buccal swab and blood sample collection
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Complete response (CR) rate
Tijdsspanne: Up to 4 cycles of treatment
|
Will be assessed using the International Working Group 2023 (IWG2023) criteria. Will compare the CR rate between the two treatment arms to determine if patients treated with enasidenib + ASTX727 have a statistically significantly higher CR rate than patients treated with the ASTX727 monotherapy. |
Up to 4 cycles of treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Event-free survival (EFS)
Tijdsspanne: Time from randomization to either a failure to achieve a CR, CR with limited count recovery (CRL), or CR with partial count recovery (CRh) after four cycles of treatment, relapse, or death due to any cause, assessed up to 18 months
|
Sensitivity analyses will be conducted. Will use the methods of Kaplan-Meier as well as Cox regression models. |
Time from randomization to either a failure to achieve a CR, CR with limited count recovery (CRL), or CR with partial count recovery (CRh) after four cycles of treatment, relapse, or death due to any cause, assessed up to 18 months
|
|
Overall survival (OS)
Tijdsspanne: Time from randomization to death due to any cause, assessed up to 18 months
|
Will use the methods of Kaplan-Meier as well as Cox regression models. |
Time from randomization to death due to any cause, assessed up to 18 months
|
|
Time to response
Tijdsspanne: Time from randomization to documented response, assessed up to 5 years
|
Will be assessed only among patients who achieve a response (CR, CRL, or CRh). Will utilize the methods of Kaplan-Meier as well as Cox regression models. |
Time from randomization to documented response, assessed up to 5 years
|
|
Duration of response
Tijdsspanne: From patient first achieves a response until either progression or death, assessed up to 5 years
|
Will be assessed only among patients who achieve a response (CR, CRL, or CRh). Will use the methods of Kaplan-Meier as well as Cox regression models. |
From patient first achieves a response until either progression or death, assessed up to 5 years
|
|
Incidence of adverse events
Tijdsspanne: Up to 4 weeks after completion of study treatment
|
Will be determined using the Common Terminology Criteria for Adverse Events version 5 criteria. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. Will review all adverse event data that is graded as 3, 4, or 5 and classified as either "unrelated" or "unlikely to be related" to study treatment in the event of an actual relationship developing. The incidence of severe (grade 3+) adverse events or toxicities will be described for each treatment arm, but will also be compared between the arms. Fisher's exact tests will be used to quantitatively compare the incidence of severe as well as specific toxicities of interest and will graphically assess differences in maximum grades observed for toxicities. |
Up to 4 weeks after completion of study treatment
|
|
Change in IDH2 variant allele frequency (VAF)
Tijdsspanne: Baseline to end of cycle 4 and 6
|
Will report the percent change of VAF along with a 95% confidence interval. |
Baseline to end of cycle 4 and 6
|
|
Allogeneic stem cell transplantation rate
Tijdsspanne: Up to 5 years
|
Will report along with a 95% confidence interval for each treatment arm. |
Up to 5 years
|
|
Measurable residual disease rate
Tijdsspanne: At the end of cycle 4 and 6
|
Will be measured by flow cytometry and next generation sequencing. Will be compared and used to determine association with clinical outcomes such as CR, EFS, or OS. |
At the end of cycle 4 and 6
|
|
Cytogenetic and molecular features
Tijdsspanne: Up to 5 years
|
Cytogenetic and molecular classifications including Molecular International Prognostic Scoring System will be compared and used to determined association with clinical outcomes such as CR, EFS, and OS. |
Up to 5 years
|
|
Time to transformation of myelodysplastic syndrome to acute myeloid leukemia (AML)
Tijdsspanne: From randomization to transformation to AML or death from any causes, assessed up to 5 years
|
Will utilize the methods of Kaplan-Meier as well as Cox regression models. |
From randomization to transformation to AML or death from any causes, assessed up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Anand A Patel, Alliance for Clinical Trials in Oncology
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hematologische ziekten
- Beenmergziekten
- Hemische en lymfatische ziekten
- Myelodysplastische syndromen
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Diagnostische technieken, chirurgisch
- Biopsie
- Exemplaarbehandeling
- Decitabine en combinatie van cedazuridine
- enasidenib
Andere studie-ID-nummers
- NCI-2024-07049
- U10CA180821 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2024-07049 (Register-ID: CTRP (Clinical Trial Reporting Program))
- MM1MDS-A01 (Andere identificatie: CTEP)
- MM1MDS-A01 (Andere identificatie: Alliance for Clinical Trials in Oncology)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .